Ncardia Established Following Pluriomics Axiogenesis Merger
Ncardia (www.ncardia.com) has been established following the merger of Pluriomics and Axiogenesis. The privately held company with operations in Europe and the US, produces and commercializes high-quality, fully functional hiPSC derived cardiovascular and neuronal cell types and develops and realizes electrophysiology, biochemistry and contraction based assays for predictive safety pharmacology, toxicology testing and drug efficacy screenings.
Ncardia has secured an additional €4.25M from existing investors, Vesalius Biocapital, SFPI-FPIM and Sambrinvest as a direct result of the merger. Both scientific specialists & business units based in the Netherlands, Germany, Belgium and the US are focused on meeting the needs of customers in pharma and biotech sectors and have developed a pipeline of innovative products, services and solutions to position Ncardia as the trusted global leader in hiPSC based cardiac drug discovery & development. Dr. Stefan Braam, Pluriomics co-founder has been appointed CEO while Dr. Heribert Bohlen, Axiogenesis co-founder has been named CSO. Dr. Bernd Fronhoff will become COO.
“Establishing Ncardia was a strategic decision” said Stefan Braam CEO. “We are bringing the best of both organisations together – our people, products, services, industry knowledge and expertise to develop and generate more innovative stem cell based products and services to serve our customers at an even higher level than before. Our goal is to be the trusted global leader in the hiPSC drug discovery and development field so that Ncardia is the partner of choice for scientists operating in cardiovascular and neural safety and efficacy projects.”
By joining forces, Ncardia can provide assay solutions in a shorter time-frame which will help to accelerate and improve the discovery & development of efficient and safe drugs. The combined business allows Ncardia to build on over two decades of knowledge, stem cell product R&D and commercialization by Pluriomics and Axiogenesis respectively. It gives Ncardia further opportunities for growth in a rapidly developing marketplace.
Heribert Bohlen CSO added, “Combining the scientific excellence and expertise of Pluriomics and Axiogenesis boosts our R&D capabilities. It allows us to accelerate innovations within the cardiac drug discovery & development areas. He went on to say that “the combined specialist units will allow our customers to accelerate and improve drug candidate selection, lower costs, and ultimately increase drug development efficiency.“
Ncardia has more than 60 employees in Europe and the US. The combined teams will continue to engage with clients to develop and provide customers with a broad portfolio of cardiovascular cell models and services. These services range from disease modelling to cardiovascular drug efficacy screening to cardiac safety assessment and implementing Ncardia’s innovative and proprietary cell types in various screening platforms.
For more information visit www.Ncardia.com or contact:
Ncardia (www.ncardia.com) believes that stem cell technology will help to get better medicines to patients faster. The company develops, produces and commercializes highly predictive human cellular assay systems for safety and efficacy testing. The cardiac product portfolio encompasses a broad panel of hiPSC derived Cardiomyocytes (Pluricyte®, Cor.4U® and vCor.4U®) as well cardiac fibroblasts (FibroCor.4U®). In addition, the company delivers the CardioplateTM product line of quality controlled ready to use assay plates. The neural cell portfolio contains the pan-neuronal product CNS4U, the peripheral neurons product Peri.4U®, and astrocyte product Astro.4U®.
Ncardia is committed to deliver its clients working assays solutions through in house assay development and extensive support. The company has a wide range of supported applications and compound assay services such as of electrophysiology, biochemistry and contraction based assays for predictive safety pharmacology and toxicology testing. In addition, Ncardia develops and provides its customers with a broad portfolio of cardiovascular services from disease modeling to cardiovascular drug efficacy screening.
Ncardia is based in Belgium, The Netherlands, Germany and in the USA. The company is privately held and established following the merger of Pluriomics and Axiogenesis.
Celine Hechard, PhD
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
SquareWell Partners Officially Launches Today to Assist Companies in Navigating the Evolving Demands of Investors25.9.2018 09:00 | Tiedote
SquareWell’s unique approach, supported by its proprietary technology, was developed out of the founding partners’ recognition of the need to optimize company-investor engagement practices and support proactive management of environmental, social and governance (ESG) risks for maximum impact. Over the last 15 years, the prominence of ESG issues has risen dramatically in the capital markets and knowing what investors prioritize and how best to communicate with them remains a challenge for companies. Furthermore, activism is no longer just an investment strategy but has become a mainstream behavior. SquareWell acknowledges this changing dynamic and facilitates progress by providing companies with year-round strategic advice regarding their investors. With SquareWell’s support, companies are better able to anticipate and identify risks and opportunities associated with long-term strategic issues, ranging from capital allocation to supply chain oversight. By analyzing existing data and lev
FRISS Survey Reveals Big Bang of Digital Transformation in Insurance is Yet to Come25.9.2018 08:30 | Tiedote
Today, FRISS, the worldwide provider of AI powered fraud and risk solutions for the P&C insurance industry, released the “Digital Transformation in Insurance Survey 2018”. The survey was initiated to get a better understanding of the current market state, uncovering emerging global trends in P&C insurance regarding digital transformation. Over 170 insurance professionals participated, from various countries across the globe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924005072/en/ FRISS launches Digital Transformation in Insurance Survey 2018 Digital transformation provides the insurance industry with the opportunity to use technology in order to improve efficiency, customer satisfaction and realize new strategic opportunities. These opportunities could create new services or business models and improved efficiency. Digitalization also opens doors to improve customer experience. However, digitalization can also result
AMPLEXOR a Gold Plus Sponsor of the 2018 NORDIC TechKomm in Copenhagen25.9.2018 08:03 | Tiedote
AMPLEXOR, a top-10 global language solutions provider, is a Gold Plus Sponsor and presenter at this year’s NORDIC TechKomm in Copenhagen on 26–27 September. This two-day event brings together experts from all over Europe to share best practices and present current ideas on the main conference topic, "How to make your documentation intelligent today." NORDIC TechKomm is geared toward professionals in technical communication eager to learn and share their knowledge about the latest industry trends. Attendees can expect to learn about creating effective and engaging content, ensuring documentation teams are self-sustainable, understanding the importance of AI and technical communication and more. At the 2018 NORDIC TechKomm, AMPLEXOR’s Manager of Strategic Accounts and augmented reality (AR) expert, Gilberto Picareta, will present, “Augmented Reality and Technical Authoring.” The presentation will discuss how AR is impacting technical information and communication, how to incorporate and
Veezi Signs Deal with CanalOlympia, Vivendi's Pan African Cinema Network25.9.2018 08:00 | Tiedote
Vista Group International (NZX & ASX: VGL) company Vista Entertainment Solutions (‘Vista Cinema’) and Vivendi’s CanalOlympia have signed an agreement to roll-out Vista Cinema’s Veezi across all their cinema venues. Veezi, already utilised by cinemas in 27 countries, is Vista Cinema’s SaaS cinema management solution for Independent cinemas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924006098/en/ Currently operating 9 venues across 7 countries, CanalOlympia is the leading network of cinema and live performance venues in Africa. Several additional sites are set to open in the months to come, extending the breadth of the CanalOlympia footprint. The CanalOlympia operation showcases the diversity of African culture and has helped bring cinemas back to countries currently short on entertainment choices and cultural infrastructure. The venues include the latest projection and sound technologies. They produce their own electr
Panasonic's Multi-hop HD-PLC Adopted as Smart Meter Communications System by Taiwan Power Company25.9.2018 07:27 | Tiedote
Panasonic Corporation has successfully proposed adoption to Taiwan Power Company of its HD-PLC (*1) high-speed power line communications technology as a communications system to utilize next-generation smart meters. Taiwan Power Company began accepting proposals for technology relating to communications systems in June 2017. Verification testing of the latest wireless technology and power line communications technology was held in Taipei City in September of that year. Smart meters will be introduced to approx. 260,000 households in main cities of Taiwan from December 2018. The HD-PLC technology meets the high performance criteria required, and smart meters incorporating this technology will be introduced in Taipei and other areas. Smart meters require stable communications performance to achieve detailed controls matching power demand with high-frequency data collection. The HD-PLC technology can meet these requirements and is expected to contribute to building IoT communications infr
IFF Announces Pricing of $1,500,000,000 Senior Notes Offering25.9.2018 01:25 | Tiedote
Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF), a leading innovator of sensorial experiences that move the world, today announced that it has priced its public offering of $300,000,000 aggregate principal amount of its 3.400% senior notes due 2020, $400,000,000 aggregate principal amount of its 4.450% senior notes due 2028 and $800,000,000 aggregate principal amount of its 5.000% senior notes due 2048. IFF intends to use the net proceeds from the offering to pay a portion of the consideration for the previously announced merger with Frutarom Industries Ltd. and to pay related fees and expenses. IFF anticipates that the offering will close on September 26, 2018, subject to customary closing conditions. The offering is not contingent upon the consummation of the merger. If the closing of the merger has not occurred on or prior to February 7, 2019, or, if prior to such date, the merger agreement with Frutarom is terminated, IFF will be required t
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme